Clinical Trial Update: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms [Phase 1]

View source ↗

Summary

Phase I trial update indicates ONC206 is being studied for recurrent and rare primary central nervous system neoplasms and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Meningioma
• Diffuse Midline Glioma H3 K27m-mutant
• Ependymoma
• Glioblastoma
• Medulloblastoma
• Oligodendroglioma
• Pleomorphic Xanthoastrocytoma

Drugs mentioned

• ONC206 (ONC206)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Central Nervous System Neoplasms, Glioblastoma | Phase 1 | Status: RECRUITING